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Abstract
Background: To explore the activity of pazopanib (P) + sirolimus (S) in patients who progressed after previous
clinical benefit on pazopanib.
Methods: Eight patients with progressing metastatic high grade soft tissue sarcoma (STS) whose disease advanced
on P following a response duration of at least 4 months were offered re-challenge of P supplemented by off-label S
and a single patient with progressing metastatic chondrosarcoma was offered the combination as compassionate
treatment. Patients were treated in two centers: Hadassah Medical Center and Tel Aviv Medical Center. Patients
received oral P 200–600 mg once a day supplemented by S 3–4 mg taken separately, 12 h after the P dose.
Results: Patients received treatment from December 2012 to February 2016. Four progressed on the combination
and their treatment was terminated. Two patients were undergoing treatment when data was summarized. Best
Response Evaluation Criteria in Solid Tumour (RECIST) responses were: one partial response (PR), four stable disease
(SD), and four progressive disease (PD), corresponding to five PR and four PD on the Choi criteria. Median progression
free survival was 5.5 months (range 4–17).
Conclusions: Our series showed that the combination of P + S has activity in STS patients selected by previous
response to P and in a patient with chondrosarcoma, suggesting this can serve as a mechanism to reverse resistance
to P and extend the chemotherapy-free window.
Keywords: Sarcoma, Solitary fibrous tumor, Chondrosarcoma, Pazopanib, Sirolimus, VEGF, mTOR, Tyrosine kinase
inhibitor, Resistance
Background
Soft tissue sarcoma (STS) treatment arsenal included
until 2012 only chemotherapies given as single agents or
in combination [1]. Many of these chemotherapy proto-
cols produce serious, intolerable toxicities such as pan-
cytopenia, alopecia and nephrotoxicity. Pazopanib (P), a
vascular endothelial growth factor (VEGF) receptor in-
hibitor was granted approval by the FDA and EMA for
the treatment of STS patients in second line and beyond.
According to the registration trial, the PALLETE trial, P
increased mean progression free survival (PFS) by
3 months compared to placebo with a manageable
toxicity profile comprised mainly of fatigue, diarrhea,
hypertension and hair hypopigmentation that differs sig-
nificantly from that of chemotherapy [2].
Other classes of targeted drugs were evaluated in STS
but none possessed convincing clinical benefit. One of
these classes consists of mammalian target of rapamycin
(mTOR) inhibitors, a class of drugs with anti-proliferative
effects supporting their role as anti-cancer agents [3]. Sir-
olimus (S) was the first drug in the class to be evaluated as
an anti-cancer agent and remains the most convenient
because of its low price and favorable toxicity profile
[4]. S has been tried in a sample of sarcoma patients
alone and in combination with chemotherapeutic agents
such as cyclophosphamide and gemcitabine with intri-
guing results [5–9].* Correspondence: danielakatz@hadassah.org.il1Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center,
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However, much of the recent research has been per-
formed using newer patented agents within this family,
such as ridaforolimus and everolimus. Ridaforolimus, a
new mTOR inhibitor analogue, was the only compound
to be evaluated as a maintenance agent in metastatic
STS. The study demonstrated a PFS increase of 3.1 weeks
[10]. Although this study exhibited tumor growth con-
trol, it lacked the clinical significance to allow approval
for use by any drug legislation agency. Everolimus was
studied in combination with sorafenib, a VEGF receptor
inhibitor among others, in patients with unresectable
osteosarcoma which showed a 45 % PFS but fell short of
the target endpoint 50 % 6-month PFS and was therefore
considered negative [11].
As responses to pazopanib are rarely durable and re-
sistance develops in the absence of additional evidence
based target therapies, chemotherapy is recommended.
However, reversal of resistance may as well be sought,
especially in those cases where pazopanib has been well
tolerated offering advantageous quality of life over
chemotherapy [12–14]. Emerging preclinical and clinical
data for multikinase and mTOR inhibitors relies on the
mechanistic hypothesis that the combination blocks
angiogenesis at two different points in the signaling
pathway and suggests that their concomitant administra-
tion after progression on pazopanib has the potential to
offer further disease stabilization and prolong the
chemotherapy-free window [15, 16].
Here we report on a retrospective series of eight unre-
sectable metastatic advanced STS patients and one
chondrosarcoma patient treated with P + S.
Methods
Patients with progressing metastatic unresectable high
grade STS, whose disease advanced on P following a re-
sponse duration of at least 4 months were offered re-
challenge of P supplemented by off-label S in two med-
ical centers; Hadassah Medical Center and Tel Aviv
Medical Center. A single patient with progressing unre-
sectable metastatic chondrosarcoma resistant to chemo-
therapy was offered the combination as compassionate
treatment. All patients were in good performance status
with an ECOG 0–1. Patient data collection was initiated
following local IRB approval.
Treatment schedule and evaluation
Patients received oral P 200–600 mg once a day supple-
mented by S 3–4 mg taken separately, 12 h after the P
dose. In those cases in which serum S levels were mea-
sured 7–14d after treatment was started, S dose was ad-
justed for a serum level of 15–20 ng/ml. Drug dosage
was reduced according to toxicity. Prior to the initiation
of the combination therapy, chest, abdomen and pelvis
contrast CT or PET-CT were done and repeated at 6–8
w intervals and after 6 months at 12 w intervals. Patients
with response or stable disease (SD) continued treat-
ment until disease progression (PD). Blood tests were re-
peated bi-weekly in the first month and monthly
thereafter. Toxicity was recorded at each clinic visit and
summarized in Table 1.
Outcome evaluation
Response was assessed according to the Response Evalu-
ation Criteria in Solid Tumors (RECIST) (version 1.1)
and Choi criteria. According to Choi criteria, response is
based on both a minimum of a 10 % reduction in size
and a 15 % reduction in density. Progression was defined
as new lesions, an increase in ≥10 % in tumor size with-
out meeting any criteria for a PR according to tumor
density/contrast enhancement, or an increase ≥15 % in
tumor density/contrast enhancement. PFS was calcu-
lated from the first date of treatment to the date of doc-
umented progression according to RECIST. Overall
survival was computed from first date of treatment to
the date of death or last date of follow up.
Results
Between December 2012 to February 2016, nine patients
received P + S in combination. Four patients progressed
on the combination and their treatment was terminated.
Two patients were undergoing treatment when we sum-
marized the data.
Eight patients (five females); 2 solitary fibrous tumor
(SFT), 2 undifferentiated pleomorphic sarcoma (UPS), 1
uterine leiomyosarcoma (ULMS), 1 leiomyosarcoma
(LMS), 1 desmoplastic small round cell tumor (DSRCT),
1 undifferentiated uterine sarcoma (UUS) between the
ages of 36–74 received P + S in combination, following
escape from response to P of at least 4 months and one
patient with grade II metastatic chondrosarcoma re-
ceived the combination without initial P (Table 1). Pa-
tients ages ranged between 20 and 74 years old.
Five patients (5/8) benefited from the combination.
Best RECIST responses were one PR (patient #4 with
UPS), four SD and four PD. Median PFS was 5.5 m
(range 4–17). Two patients are still on treatment (pa-
tients 5 and 9). Four patients are alive. Patient #5 under-
went two consecutive resections of three lung
metastases (right middle lobe, subpleural and left lower
lobe) after completing 6 m of P + S (P 200 mg + S 4 mg)
with SD as best response according to RECIST and PR
according to Choi (see Fig. 1). Prior to treatment initi-
ation, she was rapidly progressing on P single agent.
Baseline CT demonstrated a new right lung lesion com-
pared with CT 6 weeks prior. On Pathology the RML le-
sion was completely fibrotic, the left sub-pleural lesion
consisted of extensive necrosis with scarce residual sar-
coma cells and the left lower lobe lesion was composed
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mainly of viable sarcoma tissue. The patient’s treatment
was discontinued following the oligo-metastasectomy.
Three months later, chest CT demonstrated a new RML
lesion and treatment with P + S was resumed (P 200 mg
+ S 4 mg). Following 7.5 months of stable disease,
stereotactic body radiotherapy (SBRT) was administrated
to the single right middle lobe lesion while the patient’s
treatment continued.
There was one serious adverse event of small bowel
perforation after 5 months on treatment, which was sur-
gically treated with complete recovery. On pathology, a
necrotic metastasis was present on the wall of the small
bowel at the site of perforation. Additionally, two pa-
tients developed hyperglycemia compliant to metformin,
one patient complained of lethargy. Overall, treatment
was very well tolerated without added side effects.
Discussion
We assessed the efficacy of the combination P + S in a
series of eight patients with unresectable metastatic high
grade STS and one patient with grade II chondrosar-
coma. Currently, there are no evidence-based molecular
predictive markers for response to tyrosine kinase inhib-
itors [17]. In order to optimize the chance of response,
we enriched the treatment group with patients who had
already shown benefit from P alone and escaped re-
sponse, with the hope that this strategy would reverse
resistance and delay the use of cytotoxic compounds.
This study was not designed to delineate efficacy by STS
subtype, but rather serve as a proof of concept that P + S
is an effective way to combat resistance to P and prolong
PFS. Out of the nine patients, four had S levels mea-
sured 7–14d after treatment was started and S dose was
adjusted for a serum level of 15–20 ng/ml. However,
since three patients responded despite not having their
levels adjusted, we cannot determine that there is a cor-
relation between blood level and response.
After the addition of S, we noticed additional limited
toxicity. Only one patient developed a serious adverse
event (SAE) (small bowel perforation) necessitating
hospitalization and surgery with complete recovery. Of
mention, the toxicity observed in this patient was related
to the efficacy of the combination on the tumor, which
was located on the wall of the small bowel. Less serious
side effects developed in three patients; two patients de-
veloped hyperglycemia controlled by metformin and one
patient developed a drug fever, which resolved over time.
Overall, most patients tolerated the addition of S well.
With the exception of the SAE above, there were no
additional hospital admissions due to side effects from
therapy. In terms of activity, 56 % (5/9) of the patients
had a PFS of at least 5 months from the initiation of
combination therapy. Following progression on the com-
bination therapy, all STS patients received an additional
line of chemotherapy.
We proposed supplementing P with S for various rea-
sons. S has a favorable toxicity profile, its levels can be
monitored, and preclinical and clinical data suggests that
the combination with a VEGF receptor tyrosine kinase
inhibitor (TKI) may potentially reverse resistance [8, 11,
15, 16, 18]. Pazopanib is a multikinase inhibitor that
blocks the VEGF and PDGF receptors. However, ac-
quired resistance to P eventually develops [12, 13, 19].
There are several potential mechanisms for the develop-
ment of resistance; the most relevant being a compensa-
tory increase in VEGF levels. As P blocks the VEGF
Fig. 1 Response to P + S combination therapy. Computed tomography (CT) scan (arterial phase after contrast medium) of the chest. (a) Baseline (b) Six
months after starting P + S combination therapy. Arrows indicate the response observed in the intrathoracic lesion, marked by decrease in tumor density
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receptor, hypoxia develops secondary to the negative ef-
fects of the receptor blockade on angiogenesis, leading
to regression of blood vessels and an increase in HIF-1a
levels via the mTOR pathway [18]. HIF-1a upregulates
production of target genes including VEGF in the tumor
microenvironment (Fig. 2). mTOR inhibition offsets the
production of VEGF through complementary inhibition
of the PTEN-AKT-mTOR pathway [20].
Another important adaptive mechanism of resistance to
P is upregulation of fibroblast growth factor 2 (FGF2) [21].
FGF activates the FGF receptor inducing angiogenesis
through the mTOR signaling pathway, along with several
other pathways. Abrogating the mTOR pathway amelio-
rates angiogenesis induced by FGF2 [22]. On a different
note, platelet derived growth factor receptor a (PDGFRa)
was found to be activated by mTOR inhibition [22].
Therefore, combining S with an PDGFR inhibitor such as
P may overcome potential resistance [23]. Furthermore, in
the phase III SUCCEED trial designed to assess efficacy of
single agent oral ridaforolimus on patients with STS, there
was proof of tumor growth control, albeit clinically insig-
nificant. The results of this trial support the use of
combination therapy with other signaling inhibitors to
overcome the activation of possible intracellular compen-
satory signaling pathways [10].
The rationale for adding mTOR inhibition to reverse
resistance is not novel. The mTOR inhibitor everolimus
was combined with an aromatase inhibitor exemestane
in breast cancer patients who progressed while receiving
an aromatase inhibitor. The results showed that adding
everolimus increased PFS by 4.1 months [24]. In breast
cancer, resistance to endocrine therapy is mediated
through mTOR-induced phosphorylation of estrogen re-
ceptors and the addition of everolimus disrupts this
phosphorylation and resulting resistance [25, 26]. An
additional study evaluated the effect of the multikinase
inhibitor, sorafenib, and the mTOR inhibitor, everolimus,
in patients with metastatic osteosarcoma. The clinical
benefit rate (CBR) at 6 months was 45 % with combin-
ation therapy, while another phase II study in a similar
population showed a CBR of 29 % at 6 months for soraf-
enib alone [11, 15]. The study suggests that in osteosar-
coma, resistance to sorafenib is mediated, at least partly,
through the mTOR pathway. Sorafenib suppresses the
mTORC1 pathway but simultaneously activates mTORC2
which promotes tumor progression. Adding the mTOR
inhibitor everolimus overcomes this resistance. Regardless
of the type of cancer, mTOR is a universal mediator of
protein synthesis affecting angiogenesis and proliferation
and mechanistically its inhibition may circumvent
resistance [27].
Patient #5 exhibited an “exceptional” response to P + S
treatment. This patient underwent next generation se-
quencing (NGS) using the Foundation One test which
showed a mutation in TSC2 splice site 2545. TSC2 is
part of the TSC1-TSC2 complex, which inhibits
mTORC1 through its Rheb-GAP activity. When the
complex is active, the levels of Rheb-GTP decrease, in-
activating mTORC1 and blocking its cell growth promo-
tion (see Fig. 3). A mutation in TSC1 or TSC2 can lead
to loss of function and constant activation of the
mTORC complex [28]. This patient had a specific TSC2
mutation that had not been described in malignant tis-
sue in COSMIC as of February 2016. However, it is
known that TSC2 splice site alteration affects exon 22
Fig. 2 Compensatory VEGF overexpression. Initiation of pazopanib
leads to a decrease in angiogenesis and development of hypoxia.
Hypoxia causes an increase in HIF-1a levels, leading to increased
production of target genes including VEGF. mTOR inhibition may
stop this compensatory increase
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and causes protein truncation [29]. This leads to inacti-
vation of the GTPase domain of the TSC1-2 complex,
leading to constant downstream activation of mTORC1
and cell growth.
We included one patient with a paratracheal unresect-
able grade II chondrosarcoma (#9) who had failed doce-
taxel in combination with gemcitabine. The P + S was
offered as compassionate therapy given the lack of add-
itional treatment options. The patient exhibited a rapid
clinical response to the combination with resolution of
chest pain, shortness of breath, and no re-accumulation
of a pleural effusion that had previously been tapped.
CT findings three months later confirmed the clinical
improvement showing liquidification of the tumor with
stabilization of disease (see Fig. 4). The patient’s P + S
treatment is ongoing.
As previously mentioned, this study was not intended
to evaluate efficacy by sarcoma subtype. However, two
patients with metastatic SFT progressed on the combin-
ation therapy. In a study that evaluated P efficacy in
SFT, a lower level activity was reported for P compared
to sumitinib and bevacizumab plus temozolomide. This
lower level of response was supported by preclinical
data. Therefore, it is possible that progression on the
combination seen in our study suggests real resistance
within this subtype [19].
As seen with P alone, disease stabilization as defined
by RECIST is the most frequent response in this series.
However, Choi criteria assesses a change in density as
Fig. 3 TSC1-2 complex activation and effect on mTOR pathway.
TSC1-2 forms a complex with the GTPase domain of Rheb, converting
it to its inactive, Rheb-GDP form. A loss of function mutation in TSC1-2
leads to increased levels and unopposed action of Rheb-GTP on
mTORC1, leading to constant cell growth. Additionally, loss of function
of TSC1-2 hinders mTORC2 activation
Fig. 4 Response to P + S combination therapy in grade II paratracheal chondrosarcoma. Computed tomography (CT) scan. Three months after
starting P + S combination therapy a response was observed in the form of tumor liquidification and stabilization of disease
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well as size of the target lesions and therefore appears to
be a better predictor of clinical response [30]. In our
sample, all of the patients with SD by RECIST were con-
firmed to exhibit PR according to Choi.
Our clinical data, even if retrospective and on a small
heterogenic group of patients, confirms that P + S was
active in more than half of the patients. However, a po-
tential limitation of this study is that response to single
agent S following resistance to P was not tested. It is
possible the patients in this study who benefited from P
+ S could have also benefited from S alone. However,
combination P + S did not add significant additional tox-
icity, with its only downside being the additional cost. A
future randomized control trial comparing P + S to S
alone following resistance to P may further elucidate
whether combination therapy is necessary. Because the
arsenal of treatments in sarcoma is limited, any benefit
observed by this combination therapy should be further
investigated.
Conclusion
Our series showed that the combination of P + S has activ-
ity in STS and chondrosarcoma patients selected by previ-
ous response to P. The goal of therapy for patients with
metastatic sarcoma is to prolong life and palliate symp-
toms. Thus the favored approach remains to use less toxic
drugs. P is currently the only approved targeted small
molecule in second-line and beyond treatment in STS
with a favorable toxicity profile which differs greatly from
that of chemotherapy. Resistance to P eventually develops
and the addition of S serves to prolong the chemotherapy-
free window. This retrospective series proposes to
enhance the therapeutic landscape of STS patients. We
suggest that the current results serve as proof of concept
for the use of combination P + S after escape from P and
should be explored prospectively in a large randomized
control trial to evaluate the efficacy of combination ther-
apy in different sarcoma subtypes.
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